Global Melanoma Treatment Market Poised to Surpass $12 Billion by 2028, Driven by Advances in Immunotherapy and Targeted Therapies - ResearchAndMarkets.com

20 Dec 2023
www.businesswire.com
Immunotherapy
DUBLIN--(BUSINESS WIRE)--The "Melanoma TherapeuticsMelanoma Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering.
The global market for melanoma treatment was estimated to reach $6.8 billion in 2022 and is expected to reach $12.1 billion through 2028, growing at a CAGR of 10.2% during the forecast period.
Major players in the market include Merck & Co., Bristol Myers Squibb and Novartis. Apart from the major players there are also small biotech companies such as Erasca, HUYABIO International and IO Biotech that have promising drug candidates in the pipeline, which should push market growth during the forecast period.
Growth Drivers:
The analysis disclosed in this publication stresses the instrumental role of modern medical interventions, such as the introduction of immune-checkpoint inhibitors and small molecule-targeted therapies, in revolutionizing the treatment landscape for advanced melanoma. With a compound annual growth rate (CAGR) of 10.2% projected from 2022 through 2028, the melanoma treatment sector is witnessing an uptrend, underpinned by increasing drug approvals and surging patient survival rates. Biotechnological innovations and strategic initiatives by industry leaders compound the market expansion.
Regional Insights:
The North American melanoma treatment sector emerges as the frontrunner, closely trailed by Europe, accounting for the lion's share of the global market. Factors spurring growth in these regions include heightened healthcare expenditure, public awareness campaigns, and supportive government frameworks. In particular, immunotherapies dominate the therapeutics segment, claiming the majority market share in 2022.
Vital Segmentation:
The research delves into the segmentation of the melanoma treatment market by treatment type, cancer stage, and therapeutics. The localized stage of melanoma garners considerable attention due to the high success rates of surgical interventions, which remain the primary treatment approach.
Pipeline Analysis:
With a spotlight on the promising treatment pipeline, the publication highlights the continuous emergence of first-in-class molecules targeting novel aspects of melanoma. A burgeoning focus on personalized medicine, epitomized through innovative cell therapies and vaccines, showcases a commitment to tackling disease recurrence and improving patient outcomes.
Market Dynamics:
The report articulates the dual forces shaping the melanoma treatment marketplace, identifying critical stimulants such as technological progressions, enhanced detection tools, and patient advocacy. Conversely, challenges like the high costs of cutting-edge treatments and regulatory hurdles are acknowledged as potential market constraints.
Key Players:
Spotlighting the change-makers, the research profiles leading organizations and emerging biotech firms that are catalyzing paradigm shifts in melanoma therapeutics. These entities are pioneering the development of groundbreaking treatments, consequently fortifying their market position.
The report profiles the following leading players
Erasca
Moderna Ina.
Key Attributes:
Report Attribute
Details
No. of Pages
131
Forecast Period
2023 - 2028
Estimated Market Value (USD) in 2023
$7.4 Billion
Forecasted Market Value (USD) by 2028
$12.1 Billion
Compound Annual Growth Rate
10.2%
Regions Covered
Global
Key Topics Covered:
Chapter 1: Introduction
Chapter 2: Summary and Highlights
Chapter 3: Market and Technology Background
Risk Factors, Causes and Prevention
Symptoms
Pathophysiology and Clinical Subtypes
Prognosis
Epidemiology
Diagnosis
Biopsy
Laboratory Tests
Blood Tests
Imaging Tests
Treatment
Immunotherapy
Virus Therapy
BRAF inhibitors:
MEK Inhibitors
Chapter 4: Market Dynamics
Market Factors
Market Drivers
Increasing Prevalence of Melanoma
Technological Advancements and Product Launches
Strategic Initiatives
Developments in Early Detection Tools
Patient Advocacy Groups and Awareness
Market Restraints
High Cost of Treatment
Stringent Regulations
Resistance to Therapies
Market Opportunities
Chapter 5: Market Breakdown by Type
Surgery
Wide Excision
Mohs Surgery
Amputation
Lymph Node Dissection
Therapeutics by Type
Radiation Therapy
Chapter 6: Market Breakdown by Disease Stage
Localized Disease
Regional Disease
Distant Disease
Chapter 7: Market Breakdown by Region
Chapter 8: Sustainability: An ESG Perspective
ESG Challenges in the Pharmaceutical Industry
ESG Practices in the Market for Melanoma Therapeutics
Case Study
Research Viewpoint
Chapter 9: Emerging Technologies/ Developments
Adoptive Cell Therapy
Engineered TCR Therapy
Vaccines
Targeted Therapy
Chapter 10: Regulatory Landscape and Pipeline Analysis
Chapter 11: Patent Analysis
Chapter 12: Competitive Landscape
Chapter 13: Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/i3kz5h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.